Asker, Norway

Takeda as


USPTO Granted Patents = 9

% Expired Patents = 22.2



Forward Citations = 6

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Poul Bertelsen (8 out of 17 patents)

silverMedal Pernille Dybendal Pedersen (5 out of 6 patents)

bronzeMedal Henrik Neuschafer Larsen (3 out of 3 patents)

4.  Henrik Braender (3 out of 3 patents)

5.  Ingrid Blanka (3 out of 3 patents)

6.  Peder Mohr Olsen (3 out of 9 patents)

7.  Wolfgang Schoenhofer (2 out of 3 patents)

8.  Jacob Mathiesen (2 out of 2 patents)

9.  Carsten Martini Nielsen (2 out of 5 patents)

10.  Henrik Neuschaefer Larsen (2 out of 2 patents)

11.  Wolfgang Schonhofer (1 out of 1 patent)

12.  Siegfried Kirchmayr (1 out of 3 patents)

13.  Meinolf Vogt (1 out of 3 patents)

14.  Henrik Ravn Aage (1 out of 2 patents)

15.  Thomas Thisted (1 out of 2 patents)


9 patents:

Company Overview
Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Japan. With a focus on innovation and patient care, Takeda develops and markets a wide range of prescription medicines for various therapeutic areas, including gastroenterology, oncology, and neuroscience. Takeda is committed to improving the quality of life for patients around the world through its research and development efforts.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Takeda as USPTO Patent Assignee Logo
9 Patents

#4 in Asker

#195 in Norway

Asker, NO
Asker, Norway
Forward Citations = 6

16 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Takeda as. Retrieved from https://idiyas.com/company/takeda-as

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…